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Abstract
Activin, a member of the transforming growth factor-b superfamily, is an endocrine hormone that regulates differentiation
and proliferation of a wide variety of cells. In the brain, activin protects neurons from ischemic damage. In this study, we
demonstrate that activin modulates anxiety-related behavior by analyzing ACM4 and FSM transgenic mice in which activin
and follistatin (which antagonizes the activin signal), respectively, were overexpressed in a forebrain-specific manner under
the control of the aCaMKII promoter. Behavioral analyses revealed that FSM mice exhibited enhanced anxiety compared to
wild-type littermates, while ACM4 mice showed reduced anxiety. Importantly, survival of newly formed neurons in the
subgranular zone of adult hippocampus was significantly decreased in FSM mice, which was partially rescued in ACM4/FSM
double transgenic mice. Our findings demonstrate that the level of activin in the adult brain bi-directionally influences
anxiety-related behavior. These results further suggest that decreases in postnatal neurogenesis caused by activin inhibition
affect an anxiety-related behavior in adulthood. Activin and its signaling pathway may represent novel therapeutic targets
for anxiety disorder as well as ischemic brain injury.
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Introduction
Anxiety disorder represents one of the most common mental
illnesses [1–3]. Recently, disturbance in adult hippocampal
neurogenesis was proposed to underlie anxiety-like behavior in
rodents [4,5]; however, molecular mechanisms that link hippo-
campal neurogenesis to anxiety disorder remains poorly under-
stood.
Activin, a member of the transforming growth factor-b
superfamily, is an endocrine hormone that regulates differentiation
and proliferation of a wide variety of cells [6]. In the brain, activin
receptor ActRII is highly expressed in forebrain region [7,8], and
its scaffold protein ARIP/S-SCAM is also localized in synaptic
region [9,10]. Furthermore, activin protects neurons from
ischemic damage [11], and its expression is upregulated by
neuronal activity [12,13]. Recently, we showed that activin
modulates dendritic spin morphology that is important for
synaptic plasticity in the hippocampus [14,15].
In this study, we generated and analyzed transgenic mice in
which activin function in the forebrain is either suppressed or
enhanced. We found that the activin activity in the adult forebrain
influences locomotor activity, anxiety-related behavior, and
hippocampal neurogenesis.
Results
We explored the role activin plays in anxiety-related behavior
using a transgenic mouse model that overexpresses activin or
follistatin, an activin-inhibitory protein, in a forebrain-specific
manner. Disturbance of activin signal during the developmental
stage causes a lethal phenotype in mammals [16,17]. To achieve
postnatal, forebrain-specific expression, the aCaMKII promoter
was used to drive expression of a transgene (Fig. 1A) [18,19]. We
microinjected activin and follistatin transgenes into 549 and 1183
fertilized eggs, and obtained 42 and 55 weaned mice, respectively.
From these, two lines of activin transgene-integrated mice
(designated ACM3 and ACM4) and one line of follistatin
transgene-integrated mice (designated FSM) were obtained.
Transgene-integrated mice were generated in 1% of microinjected
fertilized eggs [20]. This low efficacy may have been caused by
unexpected transgene expression in various tissues during the
embryonic stage, because the activin signal is important for normal
development. In contrast to previously generated activin- or
follistatin-transgenic mice [21–23], these heterozygous transgenic
mice were fertile and bred healthily, and their body weight (data
not shown) and muscular strength were normal when compared to
their wild-type littermates (Figure S1). Since ACM3 mice showed
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hereafter describe the phenotypes of ACM4 and FSM mice.
In situ hybridization analyses of brain sections revealed that
transgene expression was restricted to the forebrain such as the
hippocampus and neocortex in the adult brain (Fig. 1B). ELISA
analyses also showed forebrain-specific expression of activin and
follistatin in ACM4 and FSM adult mice, respectively (Fig. 1C).
Low level of endogenous activin was detected in the hippocampus
and neocortex in wild-type mice. Follistatin level in FSM was
enough to antagonize this level of activin activity [24]. Follistatin
was not detected in the infant hippocampus of FSM mice
(Fig. 1C). RT-PCR revealed that follistatin- and activin-transgene
were not expressed in peripheral tissues including, heart, lung,
spleen, liver and kidney (Figure S2). Nissel staining showed no
apparent structural abnormality in the hippocampus of each
transgenic mice (Figure S3).
Open field tests were performed on transgenic mice to
investigate locomotor activity (Fig. 2). FSM mice showed a
decrease in time spent in locomotion and rearing when compared
with wild-type littermates. In contrast, ACM4 mice showed a
significant increase in rearing time. There was no genotype effect
in the walking speed (Fig. 2B) and the total pathlength (Fig. 2C),
indicating that walking ability of FSM and ACM4 mice was
normal. These results indicate that the level of functional activin in
the brain is related to general locomotor activity in a novel
environment.
In open field tests, the amount of time spent in the center of the
field is strongly correlated with an animal’s level of anxiety, a
characteristic called risk-taking behavior [25,26]. FSM mice
showed decreased performance in risk-taking behavior (Fig. 2D),
while ACM4 mice showed increased performance. To further
assess these differences, a light and dark choice test and elevated
plus-maze test were conducted. In the light and dark test, ACM4
mice accessed the lighted compartment significantly more often
than wild-type littermates (Fig. 3A), however, FSM mice spent
significantly more time in the dark compartment as compared to
wild-type littermates. In the elevated plus-maze test, ACM4 mice
spent significantly more time in the open arms of the testing
apparatus than did wild-type and FSM mice (Fig. 3B). FSM mice
showed no significant change in phenotype for this test.
Figure 1. Generation of transgenic mice and expression analysis of the transgene. (A) Schematic representation of transgene constructs.
Narrow arrows indicate the location and direction of RT-PCR primers (Figure S2). (B) Photographs of typical in situ hybridization are shown. DIG-
labeled cRNA probe corresponding to the SV40 polyA sequence was hybridized to sagittal sections of the brain from 16–22 week-old wild-type, FSM
and ACM4 mice. Scale bars, 500 mm. (C) Follistatin and activin protein levels in the hippocampus (Hip), cortex (CTX), cerebellum (Cbm) and medulla
(Med) in wild-type, FSM and ACM4 mice measured by ELISA. Results are shown as mean6s. e. m. (n=4) Except for activin in CTX in wild-type (n=1).
Adult indicates 16–22 weeks-old. P7, postnatal day 7.
doi:10.1371/journal.pone.0001869.g001
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measure anxiety levels (Fig. 3C), based on the observation that
mice generally prefer novel objects encountered in a familiar place
[27]. In this test, mice were placed in a closed box on the first day
to become familiar with the box. On the second day mice were
placed in the same box to which a cylinder with two entrances
(novel area) had been added. FSM mice spent significantly less
time accessing the novel area as compared to wild-type mice, while
the total distance they traveled during the test was normal. This
suggests that higher anxiety in FSM mice resulted in lower access
to the novel area. Taken together, the level of functional activin in
the brain modulates anxiety-related behavior. Finally, no depres-
sive behavior was observed in FSM mice in the forced swimming
test (Figure S4).
Adult neurogenesis is the production of new neurons in areas of
the adult brain including the subventricular zone (SVZ) and
subgranular zone (SGZ) of the hippocampus [28]. This formation
of new neurons plays a number of physiological roles including
damaged neuron replacement[29,30], memory formation [31,32]
and response to stress [33]. Moreover, some reports have recently
shown that neurogenesis is involved in depression [34,35].
We therefore examined adult neurogenesis in hippocampal
SGZ of FSM and ACM4 mice (Fig. 4) using 5-bromodeoxyur-
idine (BrdU)-labeling experiments. Transgenic mice were injected
with BrdU (75 mg/kg body weight) three times per day for three
consecutive days. Mice were sacrificed either 24 h or 4 weeks after
the final injection day. BrdU is incorporated into genomic DNA
by cells at S-phase, therefore, by staining with a neuronal marker
(NeuN) and an anti-BrdU antibody, newly generated neurons
were easily detected. A significant difference between FSM and
ACM4 mice was observed in the number of SGZ BrdU-positive
cells after 24 h (Fig. 4A, B). No significant difference, however,
was observed between transgenic mice and wild-type littermates,
indicating that the number of neuronal progenitor cells and the
rate of BrdU incorporation into progenitor cells in transgenic mice
were essentially normal. At the 4-week stage, however, the number
of BrdU- and NeuN-double positive cells in FSM mice was
markedly decreased (Fig. 4C). This reduction was partially
rescued by crossing with ACM4 (Fig. 4D). These results indicated
that the level of activin in the brain is crucial for the maturation
and maintenance of newly generated neurons.
The decrease in BrdU- and NeuN-double positive cells at the
4-week stage may be attributed to a decrease in the survival rate
of newly formed neurons or a decrease in the rate for neuronal
differentiation of new cells. Therefore, the change in the number
of BrdU- and NeuN-double positive cells following BrdU
Figure 2. Activin protein levels in the brain influence locomotor activity. (A) Statistical analyses of the open field test showing time spent in
locomotion and rearing [wild-type littermates (black circles), n=34; FSM (blue squares), n=18; ACM4 (red triangles), n=11]. Each plot represents an
average of 5 minutes. *, p,0.05; **, p,0.001; Fisher’s test. (B and C) Statistical analyses of walking velocity (B) and total pathlength (C) during
30 minutes of open field test. (D) Risk taking behavior test. Left panel, overhead view of the box used for open field test. #, area defined as a center
region. Mid panel, time spent in the center region during the 30 minutes of open field testing. Right panel, the percentage pathlength in the center
region. Results are shown as mean6s. e. m.
doi:10.1371/journal.pone.0001869.g002
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stages. The number of BrdU- and NeuN-double positive cells
was normal at the 1-week stage in FSM mice, suggesting a
normal differentiation rate. However, a marked decrease was
observed in the number of BrdU- and NeuN-double positive cells
at 2- and 3-week stages compared with wild-type littermates.
Therefore, in FSM mice, the survival of newly generated neurons
is significantly decreased. This indicates that activin signal is
essential for the maintenance of newly generated neurons.
Activin overexpression did not enhance the number of BrdU-
and NeuN-double positive cells at 4 weeks, suggesting that
activin overexpression is not sufficient for enhancement of adult
neurogenesis (Fig. 4C).
Taken together, FSM and ACM4 mice showed opposite
phenotypes in behavior. Furthermore, decrease in neurogenesis
in FSM mice was partially rescued in FSM/ACM4 double
transgenic mice. These results strongly suggest that the
observed effects of overexpression, either follistatin or activin,
are not positional transgene effects such as insertional
mutations.
Discussion
There is a marked overlap and coincidence between anxiety and
depression [1–3]. Depression is a serious disorder in our current
society. Many popularly prescribed antidepressant drugs work to
modulatemonoamine neurotransmission,andtakesixto eightweeks
to exert their effects [3]. Each drug is efficacious in only 60–70% of
patients. Therefore, a conceptually novel antidepressant that acts
rapidly and safely in a high proportion of patients would be highly
advantageous [3]. We show here that activin in the forebrain bi-
directionally influences anxiety-related behavior. Depression is
usually seen in anxiety patients, and anxiety is often reported in
depressed patients [1–3]. A recent paper by Dow et al. showed that
activin infusion into the hippocampus produced an antidepressant-
like effect [36]. Therefore, the level of activin in the hippocampus
modulates both depressive and anxiety-related behavior. Therefore,
activin may represent a new contributing factor for the modulation
of anxiety. The transgenic mice used in this study may be useful for
screening compounds in the development of new mechanistically-
novel anti-depressant drugs.
Figure 3. Activin protein levels in the brain modulate anxiety-related behavior. (A) Upper panels, typical traces in the light and dark test
for each genotype. Lower panels, time (%) spent in the dark compartment was measured over 30 min. Wild-type littermates (black circles), n=34;
FSM (blue squares), n=18; ACM4 (red triangles), n=11. *, p,0.05, Fisher’s test. (B) Statistical analyses of elevated plus-maze. Wild-type littermates,
n=26; FSM, n=7; ACM4, n=11. p values indicate ANOVA for genotype effect. *, p,0.05; t-test. (C) Left panels shows the apparatus used for the
novel-area accessing test. Arrows indicate points of entry to the cylinder. Small picture shows side view of the cylinder. Bar graphs show time spent in
novel area (inside cylinder) and distance traveled during 10 min testing. *, p,0.05, t-test. Results are shown as mean6s. e. m.
doi:10.1371/journal.pone.0001869.g003
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Transgene construction and generation of transgenic
mice
Coding region for mouse activin or human follistatin was
amplified by PCR using specific PCR primers designed to add a
Kozac sequence at the N-terminus and a myc-tag sequence at the
C-terminus. The resulting cDNAs were cloned into pcDNAI
(Invitrogen) to append an SV40 intron/polyadenylation signal at
the 39-end. These constructs were inserted into the Not I site of
pMM403 vector (kindly provided by Dr. M. Mayford) [18] which
contains the alpha calcium/calmodulin-dependent protein kinase
II (aCaMKII) promoter to generate pCaM-activin-Myc and
pCaM-follistatin-Myc plasmids. Sfi I fragments were isolated from
Figure 4. Activin signal is essential for survival of newly generated neurons. (A) BrdU positive cells (green) in the SGZ. Mice were sacrificed
1 day (upper panels) or 4 weeks (lower panels) after BrdU administration. At 4 weeks, most BrdU-positive cells were co-labeled with NeuN (red), a
marker for mature neurons. Propidium iodide (PI, red) was used as a nuclear marker. (B) Number of BrdU-positive cells in the SGZ. The Y-axis indicates
the number of BrdU-positive cells of the entire hippocampus. ACM4 had more BrdU-positive cells than FSM (wild-type, n=21 animals; ACM4, n=6
animals; FSM, n=10 animals). (C) Number of BrdU-positive cells differentiated to neurons (NeuN
+/BrdU
+) or differentiated to another cell type (non-
NeuN
+/BrdU
+) in the SGZ (wild-type, n=25; ACM4, n=14; FSM, n=9). Animals were sacrificed 4 weeks after BrdU administration. (D) Number of BrdU-
and NeuN-double positive cells in the SGZ (wild-type, n=32; ACM4/FSM, n=9; FSM, n=14). Animals were sacrificed 4 weeks after BrdU
administration. (E) Number of BrdU/NeuN-double positive cells in the SGZ. Animals were sacrificed 1, 2, or 3 weeks after BrdU administration. At the
2-week stage (wild-type, n=7; FSM, n=8), but not at the 1-week stage (wild-type, n=7; FSM, n=9), the number of double positive cells was
significantly decreased in FSM mice compared with wild-type littermates. Error bars indicate the s. e. m. *, p,0.05; **, p,0.01; t-test.
doi:10.1371/journal.pone.0001869.g004
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into the pronuclei of one-cell embryos of C57BL/6J mice to
produce transgenic mice [37]. Microinjected embryos were
transferred to the oviducts of pseudo-pregnant females. Founder
transgenic mice were identified by Southern blot analyses and
PCR analysis with genomic DNA prepared from tail, and bred
with C57BL/6J mice. Forward (f) and reverse (r) PCR primers for
genotyping were as follows: ACM, f-59-CACCCACTAGCCGT-
TACCAT-39and r-59-ATCCTCTCAGCCAAAGCAAG-39; FSM,
f-59-GAGGTAGGAAGAGCGATGAT-39and r-59-CTCCATCA-
TTCCCACAGAGA -39. C57BL/6J mice were purchased from
Clea Japan Inc. (Tokyo, Japan)
ELISA analysis
After removal of the brain, each neuronal tissue (hippocampus,
cortex, cerebellum and medulla) was quickly dissected out. Tissues
were homogenized in lysis buffer [5 mM Tris-HCl, pH 8.0,
0.32 M sucrose, protease inhibitor cocktail (Sigma)], and homog-
enates were centrifuged at 20,0006ga t4 uC for 10 min.
Supernatant was collected and assayed for quantification of total
protein with the BCA
TM Protein Assay Kit (Pierce). Follistatin and
activin levels were assayed by using commercial ELISA kits
(Human Follistatin Immunoassay, AN’ALYZA and Activin-A
ASSAY, Oxford Bio-Innovation, respectively).
Neurogenesis
Male mice at 5 weeks-old received daily intraperitoneal
injections of BrdU (Sigma) in 0.9% NaCl solution (75mg/kg,
three times per day for three days). Animals were sacrificed with
an overdose of anesthetics and perfused transcardially with 0.9%
saline followed by 4% paraformaldehyde (PFA) in PBS. Brains
were stored in fixative (4% PFA in PBS) for 3 h at 4uC, and
incubated overnight in 30% sucrose, and then immersed in dry ice
powder. A cryostat was used to collect sagittal sections of 14-mm
thickness. The sections were boiled for 10 min, and then treated
with 2M HCl for 30 min. After rinsing in 0.1 M boric acid
(pH 8.5) for 10 min, tissues were incubated in 1% H202 in PBS for
30 min, and then blocked with 0.1% BSA and 3% goat serum in
PBS containing with 0.1% Tween20 (PBST) at room temperature
for 1 h. After blocking, tissues were incubated with blocking
solution containing rat monoclonal anti-BrdU (1:250; Accurate)
and mouse monoclonal anti-NeuN (1:200; Chemicon) antibodies.
Sections were then incubated with anti-rat IgG-FITC and anti-
mouse IgG-Rhodamine.
For quantification, three consecutive serial sections at section-
interval 13 were used for counting BrdU-positive cells though an
640 objective (BX41, OLYMPUS) in a genotype-blinded
manner. Total number of BrdU-positive cells was obtained by
multiplying the number of BrdU-positive cells counted in all the
sections by 13/3. Figures were imaged by confocal microscopy
operated under manual control (LSM5 PASCAL, ZEISS).
Animal care and data analysis
All procedures involving mice were performed in compliance
with National Institutes of Health guidelines and were approved
by the Animal Care and Use Committee of Mitsubishi Kagaku
Institute of Life Sciences, MITILS. We abided by MITILS
guidelines on animal husbandry. All behavior experiments were
conducted in a blinded fashion on male, heterozygous transgenic
mice and their wild-type littermates (5–6 months). Two weeks
before behavioral analysis, animals were housed individually in
plastic cages and maintained on a 12:12-h light:dark cycle. Food
and water were provided ad libitum. For five days before behavioral
analysis, the mice were handled daily. Statistical analyses were
conducted using StatView (Abacus Concepts). Values were
expressed as mean6s. e. m..
In situ hybridization
To detect transgene expression the SV40 poly A signal
sequence, which is found in each transgene, was used as an
antisense probe (Fig 1A). To prepare the probe, this region was
subcloned into pBluescript II (Stratagene) to generate pSV40.
pSV40 was digested with BamHI to generate DNA template for in
vitro transcription of antisense cRNA probe. Digoxigenin-labeled
antisense cRNA probe was produced by transcription with T7
polymerase. For hybridization experiments, animals were sacri-
ficed with an overdose of anesthetics, and the brain was dissected
and immediately frozen on dry ice. Cryostat sections (20-mm
thickness) were cut and mounted onto polylysine-coated glass
slides. Sections were air-dried and stored at 280uC until use in
hybridization. In situ hybridization was carried out as described
previously [38].
Behavioral analysis
Behavioral experiments were basically carried out as described
previously [39]. In the open field test, spontaneous locomotor
activity was measured in a square arena (50650630 cm;
Muromachi Kikai, Japan) by using a device outfitted with
photo-beam detectors for monitoring horizontal and vertical
activity, namely, distance traveled, time spent in locomotion,
rearing counts and time in rearing. For statistical analysis on the
percentage pathlength in the center region, we used ImageJ
program (developed at the U. S. National Institutes of Health, and
available on the Internet at http://rsb.info.nih.gov/ij/), Mice were
allowed to explore freely while data was collected for 30 min. In
the light and dark test, the square arena was divided into light and
dark compartments. Data was collected as mice were allowed to
freely traverse the arena among the two compartments for 30 min.
The elevated plus-maze comprises areas of two opposing open
arms (256560.5 cm) and two opposing enclosed arms
(2565615 cm), connected by a central platform (O’HARA &
Co, Japan). Mice were placed in the center area, and allowed to
explore for 10 min. Their activity was recorded by video camera.
Results were analyzed on a Macintosh computer using Image
EP2.13 (O’HARA & Co), modified software of the public domain
NIH Image program (developed at the U. S. National Institutes of
Health, and available on the Internet at http://rsb.info.nih.gov/
nih-image/).
In the novel-area accessing test (Fig. 3C), mice were placed in
the center of a box (60660650 cm) for 10 min on the first day in
order to habituate the apparatus. The next day mice were placed
in the same box to which a novel cylinder (13 cm in diameter) with
two entrances (663.5 cm) was added. Mice were allowed to
explore for 10 min, while their activity was recorded by video
camera. Results were analyzed on a Macintosh computer using
Image OEC 1.02r1 (O’HARA & Co), a modified software of the
public domain NIH Image program.
Supporting Information
Figure S1 Traction test indicates that grip strength was
comparable between transgenic mice and wild-type littermates.
Forelimb grip strength was quantitatively assessed using a spring
strain gauge (O’HARA & Co., Japan). Animals held by the tail
grasped a wire netting and were gently pulled away from the bar
with a smooth steady pull until they released the wire netting. The
Y-axis indicates grip strength (g).
Found at: doi:10.1371/journal.pone.0001869.s001 (0.16 MB TIF)
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organs of FSM and ACM4 mice. RT-PCR-based identification of
transgene expression was carried out in various internal organs.
Transgene plasmid DNA and total cellular RNA prepared from
cortex of each transgenic mice line served as a positive control.
Water and total cellular RNA from cortex of wild-type mice served
as a negative control. Actin gene was used as an internal control.
Unspliced products were detected at the upper position of mature
and spliced product when transgene plasmid DNA or ACM4’s
cortex RNA were used as a template. To rule out the possibility
that genomic DNA was amplified, we performed RT-PCR
without reverse transcription (middle row panels, RT-), which
showed no signals.
Found at: doi:10.1371/journal.pone.0001869.s002 (0.56 MB TIF)
Figure S3 Nissl staining of the coronal brain section from wild-
type, FSM and ACM4. Lower panels, high magnification images
of the hippocampus. Scale bar, 500 mm. Method. Animals were
sacrificed with an overdose of anesthetics, and the brain was
dissected and immediately frozen on dry ice. Cryostat sections (18-
mm thickness) were cut and mounted onto polylysine-coated glass
slides. Sections were air-dried and stored at 280uC until use.
Slides were immersed in the 10% formalin solution for 30 min at
4uC for the fixation, and washed twice with PBS for 15 min at
room temperature. Slides were then stained with 0.1% Cresyl
Violet for 10 min. They were differentiated in H2O for 3–5 min
and then dehydrated through 70%, 95%, 100% and 100%
alcohol. They were then put in xylene and cover-slipped.
Found at: doi:10.1371/journal.pone.0001869.s003 (0.76 MB TIF)
Figure S4 Analysis of forced swimming test [wild-type litter-
mates (black circles), n=18; FSM (blue squares), n=8] on day 2.
The immobilizing time (sec) was plotted for each minute. No
significant genotype effect was observed for FSM. On day 1, mice
were placed in a container with water at a depth of 20 cm (23–
25uC) for 15 min. and forced to swim as they were unable to touch
the bottom with their hind limbs. On day 2, the mice were placed
back into 20 cm deep water for 5 min. When mice were unable to
avoid the forced swimming, they exhibited immobility. Immobility
was monitored by infra-red detector (CompACT FSS, Muromachi
Kikai).
Found at: doi:10.1371/journal.pone.0001869.s004 (0.13 MB TIF)
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